ABOUT CATO

• 

  Pro. Li Le

  Pro. Li received his Ph.D. in organic chemistry from Rutgers University under the guidance of Professor Prof. Daniel Seidel. After a postdoctoral at Yale University with Prof. Seth B. herzon, he joined Albemarle Corp as senior chemist. He moved to Sun Yat-sen University in 2015 as full Professors. His research involves:

• 

  Dr. Liang Dacheng

  Dr. Liang earned his Ph.D. degree at Sun Yat-sen University, working under the direction of Professor Albert S. C. Chan;

  Dr. Liang and co-workers developed a broad-spectrum catalytic method to facilitate SuFEx chemistry（Angew. Chem. Int. Ed. 2021, 60, 7397-7404）.

• 

  Dr. Li Xueming

  More than 8 years+ of drug R&D experience;

  Published several research papers in peer review journals such as Org. Lett. and Chem. Commun;

  Participated several-key projects such as 863, 973 and NSFC.

• 

  Dr. Cen Shuibin

  CCMA auditor, American AAFA, FDRA invited

  Participated in scientific research on rapid detection methods of SARS;

  Presided over the establishment and training of TÜV chemical testing laboratory and BV chemical laboratory.

• 

  Dr. Cui Jianfang

  Researcher in the Department of Applied Biology and chemical technology of the Hong Kong Polytechnic University;

  Engaged in coordination chemistry, metal organic chemistry and asymmetric catalysis for a long time;

Cato is professional in the research and development of chiral chromatographic separation and preparation technology, which applied to the separation and purification of compounds. Meanwhile, By taking organic synthesis methodology as innovation driving force, the chiral compound library with diverse structures has been established for convenient searh of lead compounds with physiological activities，which support the new drug research and development.

The laboratory researches the technical process route from small-scale trial production to middle production scale, controls the content of micro-impurities in mass production process of Intermediates, in order to improves the yield rate, and finally to find out the best reaction conditions and treatment methods suitable for the production of industrial-grade raw materials.

The lab covers a total of 2300 square meters with the multiple small-scale trial cells and KG level synthetic experimental zone. All the lab researchers including the ones with PhD from overseas having abundant experience in synthesis work.

The lab can independently design the route of intermediate synthesis and process amplification, realize various complex conditional reactions and obtain the accurate structural confirmation in the reaction process, also the lab is capable for the hydrogen spectrum, carbon spectrum, fluorine spectrum and various two-dimensional spectrum detection to ensure the accuracy of structural confirmation of multi chiral central compounds.

A Multi-purpose, small-scale pharmaceutical preparation platform, to verify and produce non-sterile Intermediates which is used for product verification, pilot scale-up, and can meet the requirements of particle size, crystal form, solubility, and solubility of specific projects.

So far, Cato has served more than 500 companies around the world mainly in the fields of pharmaceutical and biotechnology. The types of projects cover the whole cycle from preclinical to commercialization. By 2020, Cato has perfectly completed more than 1000 projects. CATO masters core technologies in critical technological areas such as high-end fluorine chemistry, asymmetric chiral synthesis, glycoside and biological enzyme technology, and continuous micro-reactors.